References
- Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820 doi:https://doi.org/https://doi.org/10.1007/s00401-016-1545-1.
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424 doi:https://doi.org/https://doi.org/10.3322/caac.21492.
- Chien L-N, Gittleman H, Ostrom QT, et al. Comparative brain and central nervous system tumor incidence and survival between the United States and Taiwan based on population-based registry. Front Public Health. 2016;4:151.
- Zumel-Marne A, Kundi M, Castaño-Vinyals G, et al. Clinical presentation of young people (10–24 years old) with brain tumors: results from the international MOBI-Kids study. J Neurooncol. 2020;147(2):427–440.
- Araghi M, Roshandel G, Hasanpour-Heidari S, et al. Incidence of malignant brain and central nervous system tumors in Golestan, Iran, 2004–2013. Arch Iran Med. 2020;23(1):1–6.
- Panesar SS, D’Souza RN, Yeh F-C, et al. Machine learning versus logistic regression methods for 2-year mortality prognostication in a small, heterogeneous glioma database World neurosurgery . World neurosurgery: X. 2019;2:100012 doi:https://doi.org/10.1016/j.wnsx.2019.100012.
- Helgager J, Lidov HG, Mahadevan NR, et al. A novel GIT2-BRAF fusion in pilocytic astrocytoma. Diagn Pathol. 2017;12(1):82.
- Ghiaseddin A, Reardon D, Massey W, et al. Phase II study of bevacizumab and vorinostat for patients with recurrent World Health Organization grade 4 malignant glioma. Oncologist. 2018;23(2):157.
- Rynkeviciene R, Simiene J, Strainiene E, et al. Non-coding RNAs in glioma. Cancers (Basel). 2019;11(1):17.
- Khan SR, Sikandar M, Almogren A, et al. IoMT-based computational approach for detecting brain tumor. Future Gener Comput Syst. 2020;109:360–367.
- Michaud L, Beattie B, Akhurst T, et al. 18 F-Fluciclovine (18 F-FACBC) PET imaging of recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2020;47(6):1353–1367 doi:https://doi.org/10.1007/s00259-019-04433-1.
- Özütemiz C, Neil EC, Tanwar M, et al. The role of dual-phase FDG PET/CT in the diagnosis and follow-up of brain tumors. Am J Roentgenol. 2020;215(4):985–996.
- Bark JM, Kulasinghe A, Chua B, et al. Circulating biomarkers in patients with glioblastoma. Br J Cancer. 2020;122(3):295–305. doi:https://doi.org/10.1038/s41416-019-0603-6.
- Hosseini Mojahed F, Aalami AH, Pouresmaeil V, et al. Clinical evaluation of the diagnostic role of MicroRNA-155 in breast cancer. Int J Genomics. 2020;2020 9514831 doi:https://doi.org/10.1155/2020/9514831 .
- Aalami AH, Abdeahad H, Mesgari M, et al. MicroRNA‐223 in gastrointestinal cancers: a systematic review and diagnostic meta‐analysis. Eur J Clin Invest. 2021;51(2):e13448 doi:https://doi.org/10.1111/eci.13448.
- Aalami AH, Mesgari M, Sahebkar A. Synthesis and characterization of green zinc oxide nanoparticles with antiproliferative effects through apoptosis induction and microRNA modulation in breast cancer cells. Bioinorg Chem Appl. 2020;2020 8817110 doi:https://doi.org/10.1155/2020/8817110 .
- Wang J, Che F, Zhang J. Cell-free microRNAs as non-invasive biomarkers in glioma: a diagnostic meta-analysis. Int J Biol Markers. 2019;34(3):232–242.
- Petrescu GE, Sabo AA, Torsin LI, et al. MicroRNA based theranostics for brain cancer: basic principles. J Exp Clin Cancer Res. 2019;38(1):231.
- Godlewski J, Lenart J, Salinska E. MicroRNA in brain pathology: neurodegeneration the other side of the brain cancer. Noncoding RNA. 2019;5(1):20 doi:https://doi.org/10.3390/ncrna5010020.
- McInnes MD, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. Jama. 2018;319(4):388–396.
- Xu W, Liang W, Dai Y. A three-miRNA signature as a potential biomarker for the diagnosis of glioma. Int J Clin Exp Pathol. 2017;10(3):2814–2823.
- Ivo D’Urso P, Fernando D’Urso O, Damiano Gianfreda C, et al. miR-15b and miR-21 as circulating biomarkers for diagnosis of glioma. Curr Genomics. 2015;16(5):304–311.
- Wang Q, Li P, Li A, et al. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 2012;31(1):97.
- Santangelo A, Imbrucè P, Gardenghi B, et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J Neurooncol. 2018;136(1):51–62 doi:https://doi.org/10.1007/s11060-017-2639-x.
- Zhong F, Huang T, Leng J. Serum miR-29b as a novel biomarker for glioblastoma diagnosis and prognosis. Int J Clin Exp Pathol. 2019;12(11):4106.
- Zhang H, Wang J, Wang Z, et al. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients. Cancer Biomarkers. 2019;24(1):43–49 doi:https://doi.org/10.3233/cbm-181416.
- Tang Y, Zhao S, Wang J, et al. Plasma miR-122 as a potential diagnostic and prognostic indicator in human glioma. Neurol Sci. 2017;38(6):1087–1092 doi:https://doi.org/10.1007/s10072-017-2912-y.
- Wei X, Chen D, Lv T, et al. Serum microRNA-125b as a potential biomarker for glioma diagnosis. Mol Neurobiol. 2016;53(1):163–170.
- Regazzo G, Terrenato I, Spagnuolo M, et al. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp Clin Cancer Res. 2016;35(1):124.
- Sun J, Liao K, Wu X, et al. Serum microRNA-128 as a biomarker for diagnosis of glioma. Int J Clin Exp Med. 2015;8(1):456.
- Zhang Y, Ta -W-W, Sun P-F, et al. Diagnostic and prognostic significance of serum miR-145-5p expression in glioblastoma. Int J Clin Exp Pathol. 2019;12(7):2536.
- Xiao Y, Zhang L, Song Z, et al. Potential diagnostic and prognostic value of plasma circulating MicroRNA-182 in human glioma. Med Sci Monit. 2016;22:855.
- Zhu M, Zhao W, Zhao H, et al. Diagnostic and prognostic value of microRNA‑193b in patients with glioma and its effect on tumor progression. Oncol Lett. 2019;18(5):4882–4890.
- Chen J, Yang L, Wang X. Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma. Cancer Biomarkers. 2017;20(4):521–526.
- Yue X, Lan F, Hu M, et al. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 2016;124(1):122–128.
- Lai N, Wu D, Fang X, et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer. 2015;112(7):1241–1246.
- Lan F, Yue X, Xia T. Exosomal microRNA‑210 is a potentially non‑invasive biomarker for the diagnosis and prognosis of glioma. Oncol Lett. 2020;19(3):1967–1974 doi:https://doi.org/10.3892/ol.2020.11249.
- Wang J, Che F, Zhang J, et al. Diagnostic and Prognostic Potential of Serum Cell-Free microRNA-214 in Glioma. World Neurosurg. 2019;125:e1217–e25.
- Ozdogan S, Yaltirik CK, Yilmaz SG, et al. Investigation of the effects of microRNA-221 expression levels in glioblastoma multiforme tumors. Anticancer Res. 2020;40(6):3265–3270.
- Swellam M, El Arab LE, As A-P, et al. Clinical impact of circulating oncogenic miRNA-221 and miRNA-222 in glioblastoma multiform. J Neurooncol. 2019;144(3):545–551 doi:https://doi.org/10.1007/s11060-019-03256-2.
- Lan F, Qing Q, Pan Q, et al. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell Oncol. 2018;41(1):25–33.
- Manterola L, Guruceaga E, Pérez-Larraya JG, et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 2014;16(4):520–527.
- Huang Q, Wang C, Hou Z, et al. Serum microRNA-376 family as diagnostic and prognostic markers in human gliomas. Cancer Biomarkers. 2017;19(2):137–144.
- Shao N, Wang L, Xue L, et al. Plasma miR-454-3p as a potential prognostic indicator in human glioma. Neurol Sci. 2015;36(2):309–313 doi:https://doi.org/10.1007/s10072-014-1938-7.
- Roth P, Wischhusen J, Happold C, et al. A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem. 2011;118(3):449–457.
- Yang C, Wang C, Chen X, et al. Identification of seven serum microRNAs from a genome‐wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2013;132(1):116–127.
- Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010;10(3):297–308 doi:https://doi.org/10.1586/erm.10.11.
- Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–634.
- L-h X, Guo Y, Zhang X-L, et al. Blood-based circulating microRNAs are potential diagnostic biomarkers for leukemia: result from a meta-analysis. Cell Physiol Biochem. 2016;38(3):939–949.
- Wan T, Iyer DN, Ng L. Roles of microRNAs as non-invasive biomarker and therapeutic target in colorectal cancer. Histol Histopathol. 2019 35 3 ;225–237.
- Hoshino I, Yokota H, Ishige F, et al. Radiogenomics predicts the expression of microRNA-1246 in the serum of esophageal cancer patients. Sci Rep. 2020;10(1):1–8.
- Aalami AH, Pouresmaeil V, Amirabadi A, et al. Evaluation of the diagnostic properties of serum hsa-miR-223-5p in the detection of gastric cancer: a case-control study Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2020;20(7):800–808 doi:https://doi.org/10.2174/1871520620666200204100602.
- Li L, Feng T, Zhang W, et al. MicroRNA biomarker hsa-miR-195-5p for detecting the risk of lung cancer. Int J Genomics. 2020;2020 7415909 doi:https://doi.org/10.1155/2020/7415909 .
- Rizzo M, Berti G, Russo F, et al. The miRNA pull out assay as a method to validate the miR-28-5p targets identified in other tumor contexts in prostate cancer. Int J Genomics. 2017;2017 5214806 doi:https://doi.org/10.1155/2017/5214806 .
- Yokoi A, Matsuzaki J, Yamamoto Y, et al. Integrated extracellular microRNA profiling for ovarian cancer screening. Nat Commun. 2018;9(1):1–10.
- Musaddaq G, Shahzad N, Ashraf MA, et al. Circulating liver-specific microRNAs as noninvasive diagnostic biomarkers of hepatic diseases in human. Biomarkers. 2019;24(2):103–109.
- Aalami AH, Abdeahad H, Mesgari M. Circulating miR-21 as a potential biomarker in human digestive system carcinoma: a systematic review and diagnostic meta-analysis. Biomarkers. 2021;26(2):103–113 doi:https://doi.org/10.1080/1354750X.2021.1875504.
- Zhao F, Wei C, Cui M-Y, et al. Prognostic value of microRNAs in pancreatic cancer: a meta-analysis. Aging (Albany NY). 2020;12(10):9380.
- Banelli B, Forlani A, Allemanni G, et al. MicroRNA in glioblastoma: an overview. Int J Genomics. 2017;2017 7639084 doi:https://doi.org/10.1155/2017/7639084 .
- Zhou Q, Liu J, Quan J, et al. MicroRNAs as potential biomarkers for the diagnosis of glioma: a systematic review and meta‐analysis. Cancer Sci. 2018;109(9):2651–2659.
- Huang Y, Yin J, Samawi H. Methods improving the estimate of diagnostic odds ratio. Commun Stat Simul Comput. 2018;47(2):353–366.
- Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79(1):16–20.
- Walter S. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21(9):1237–1256.
- Larner A. The Q* index: a useful global measure of dementia screening test accuracy. Dement Geriatr Cogn Dis Extra. 2015;5(2):265–270.
- Qu S, Guan J, Liu Y. Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci. 2015;348(1–2):181–187.